{"id":"NCT02611817","sponsor":"Takeda","briefTitle":"Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)","officialTitle":"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-01-04","primaryCompletion":"2019-05-06","completion":"2019-08-06","firstPosted":"2015-11-23","resultsPosted":"2020-06-23","lastUpdate":"2022-05-25"},"enrollment":644,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"DRUG","name":"Vedolizumab SC 108 mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Vedolizumab IV 300 mg","otherNames":[]}],"arms":[{"label":"Vedolizumab SC 108 mg Maintenance Arm","type":"EXPERIMENTAL"},{"label":"Placebo SC Maintenance Arm","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the effect of vedolizumab subcutaneous (vedolizumab SC) as maintenance treatment in participants with moderately to severely active CD who achieved clinical response following administration of vedolizumab intravenous (vedolizumab IV) induction therapy.","primaryOutcome":{"measure":"Percentage of Participants Achieving Clinical Remission at Week 52","timeFrame":"Week 52","effectByArm":[{"arm":"Maintenance Phase: Induction IV + Placebo","deltaMin":34.3,"sd":null},{"arm":"Maintenance Phase: Induction IV + Vedolizumab 108 mg SC","deltaMin":48,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.008"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":194,"countries":["United States","Australia","Belgium","Bosnia and Herzegovina","Brazil","Bulgaria","Canada","Czechia","Denmark","Estonia","Germany","Hungary","Israel","Italy","Japan","Lithuania","Mexico","Netherlands","Poland","Romania","Russia","Serbia","Slovakia","South Africa","South Korea","Sweden","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["38417060"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":39,"n":235},"commonTop":["Crohn's disease","Abdominal pain","Nasopharyngitis","Arthralgia","Headache"]}}